InventisBio Investor Relations

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II clinical trial to treat various cancers, such as non-small cell lung cancer and colorectal cancer with KRASG12C mutations. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase II clinical trial product for hyperuricemia and gout indications; and D-2570, a oral selective inhibitor for the treatment of autoimmune diseases such as psoriasis. In addition, the company offers preclinical products, including YF 087 for MSI high cancers, and YF550 for chromosome instability cancers. InventisBio Co., Limited was founded in 2013 and is headquartered in Pudong, China.

Read Less